Latest News & Features
Americas
Swiss-based Ferring Pharmaceuticals has prevailed in a patent dispute with rivals Serenity Pharmaceuticals and Reprise Biopharmaceuticals over a nighttime urination, or nocturia, treatment. 25 August 2020
Big Pharma
In a boost for generic pharma companies, a U-turn by the EU’s highest court removed protection for repurposed active substances, as Robert Stephen and Gareth Morgan of CMS Cameron McKenna Nabarro Olswang explain. 25 August 2020
Americas
A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior. 25 August 2020
Biotechnology
In an LSPN Connect session, Millipore’s senior corporate patent counsel, Ben Sodey, and head of legal and IP at Arbor, Kelly Morgan, shared their insights on the latest developments in this area of gene editing technology. 21 August 2020
Big Pharma
The FTC should avoid reviewing communications between Martin Shkreli and his attorneys, but these are not protected under the Privacy Act, a New York federal judge has ruled. 21 August 2020
article
A lot of strides have been made in the field of CRISPR systems, and MilliporeSigma and Arbor Biotechnologies are at the heart of developments. In this unmissable live panel, Millipore’s Senior Corporate Patent Counsel, Ben Sodey, and Kelly Morgan, Head of Legal & IP at Arbor, will share their insights on the latest developments in this arena, and answering a host of questions, including. 20 August 2020
Big Pharma
Sandoz has gathered support for its request for an en banc rehearing of a ruling that blocks it from selling a version of biologic Enbrel until 2029. 20 August 2020
Americas
Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments. 20 August 2020
Americas
Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19. 20 August 2020
Medtech
Hearing implant manufacturer Cochlear has agreed to pay an additional $75 million to settle a patent infringement case if an original $268 million damages bill is upheld by the US Supreme Court. 19 August 2020